The diabetic retinopathy market is poised for robust growth on the back of increasing prevalence of diabetes across the world. Diabetic retinopathy is a complication associated with diabetes that affects the vision of the eyes. In recent years, there has been a major increase in diabetic patients due to various reasons like sedentary lifestyle, impaired glucose tolerance, high blood pressure, and many others. In fact, as per the WHO (World Health Organization) estimates, the number of people with diabetes increase from 108 million in1980 to around 422 million in 2014.

These people are prone to several diabetic complications such as blindness, kidney failure, stroke, heart attacks, and lower limb amputation, primarily due to the late diagnosis. This has led to an increase in the demand for diabetic management treatments across the globe, predominantly creating lucrative growth opportunities for the diabetic retinopathy market growth over the forecast period.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/486  

As per a study conducted at Global Market Insights Inc., the diabetic retinopathy market is anticipated to surpass to will surpass USD 12 billion by 2025

Burgeoning demand for minimally invasive procedures is expected to accelerate the demand for laser surgeries over the forecast period. Laser treatments can be done by two methods namely, focal laser surgery and scatter photocoagulation. Focal treatment is often used to shrink particular leaking blood vessels in a minor area of the retina, generally near the macula. The ophthalmologist detects individual blood vessels for laser treatment and uses a restricted number of laser burns to seal them off.

On the other hand, scatter laser treatment is used to decrease the growth of new irregular blood vessels that have been created over a larger area of the retina. In this procedure, the ophthalmologist uses hundreds of laser burns on the retina to prevent the growth of blood vessels. People worldwide have been opting for these laser treatments due to its several features like a shorter recovery period and less post-surgical complications. On this note, studies estimate that the laser surgery segment is expected to grow at a rate of 9.2% over the forecast period.

North America diabetic retinopathy market is expected to prominent growth over the forecast period. In fact, the regional market valued at USD 3 billion in 2018. This growth can be attributed to the increasing prevalence of chronic disorders including diabetes in the region. As per the CDC (Disease Control and Prevention) estimates, over 100 million U.S. adults were living with diabetes or prediabetes phase in 2017. 

This has led to an increase in the demand for advanced medications in the region to avoid the possibility of acquiring diabetic retinopathy, thereby driving the North America diabetic retinopathy market. Moreover, surging awareness related to the availability of minimally invasive ophthalmic surgeries in the region has further impacted the business scope for diabetic retinopathy treatments over the forecast period.

Request for customization @ https://www.decresearch.com/roc/486

Leading diabetic retinopathy industry participants such as Allergan, Bayer AG, BCN Peptides, Regeneron Pharmaceuticals, ThromboGenics, Ampio Pharmaceuticals, Alimera Sciences, Kowa Company, and Novartis have been adopting numerous growth strategies like new product launches, mergers, acquisitions, etc. to tap major market share.

Citing an instance to justify the aforementioned sentence, last year, Regeneron Pharmaceuticals announced that it has received US FDA (Food and Drug Administration) approval for Eylea injection for the treatment of all stages of diabetes and decrease the risk of blindness. Such initiatives by leading industry participants are likely to accelerate the demand for diabetic retinopathy treatments over the forecast period.

The proliferative diabetic retinopathy segment is expected to record growth at a rate of 7.5% over the forecast time period. This growth can be attributed to the increasing geriatric population, which has the maximum possibility to acquire proliferative diabetic retinopathy. It is the most advanced and highly severe stage, in which blood vessels drip blood into the eye causing blurred vision. Proliferative DR is usually treated by laser surgery, which helps in shrinking the fragile blood vessels.

Partial Chapter of the Table of Content

Chapter 2. Executive Summary

2.1. Diabetic retinopathy industry 360⁰ synopsis, 2014 - 2025

2.1.1. Business trends

2.1.2. Type trends

2.1.3. Age group trends

2.1.4. Management trends

2.1.5. Distribution channel trends

2.1.6. Regional trends

Chapter 3. Diabetic Retinopathy Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2014 – 2025

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Increasing technological advancements in diabetic retinopathy surgical instruments in developed countries

3.3.1.2. Favorable reimbursement available for ophthalmologic surgeries in developed as well as developing economies

3.3.1.3. Rising prevalence of diabetes in Asia Pacific and other underdeveloped economies

3.3.1.4. Growing geriatric population in North America and Europe

3.3.2. Industry pitfalls & challenges

3.3.2.1. Post-surgical complications

3.4. Growth potential analysis

3.4.1. By type

3.4.2. By management

3.4.3. By age group

3.4.4. By distribution channel

3.5. Porter’s analysis

3.6. Competitive landscape, 2017

3.6.1. Strategy dashboard

3.7. PESTEL analysis

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/diabetic-retinopathy-market-report